Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory CLL/SLL
NCT03204188Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Sep 2017
- Primary completion
- Jul 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Complete Response at 1 year. Started Sep 2017; status: completed.
02
Drugs
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT03204188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03204188.